Melanoma, version 2.2013: Featured updates to the NCCN guidelines

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson, Adil Daud, Dominick J DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. RossSusan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian, Maria Ho

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases, and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel reached clinical consensus on clarifying the role of imaging in the workup of patients with melanoma.

Original languageEnglish (US)
Pages (from-to)395-407
Number of pages13
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume11
Issue number4
DOIs
StatePublished - Jan 1 2013

Fingerprint

Melanoma
Guidelines
Sentinel Lymph Node Biopsy
Therapeutics
Neoplasm Metastasis
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Coit, D. G., Andtbacka, R., Anker, C. J., Bichakjian, C. K., Carson, W. E., Daud, A., ... Ho, M. (2013). Melanoma, version 2.2013: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 11(4), 395-407. https://doi.org/10.6004/jnccn.2013.0055

Melanoma, version 2.2013 : Featured updates to the NCCN guidelines. / Coit, Daniel G.; Andtbacka, Robert; Anker, Christopher J.; Bichakjian, Christopher K.; Carson, William E.; Daud, Adil; DiMaio, Dominick J; Fleming, Martin D.; Guild, Valerie; Halpern, Allan C.; Hodi, F. Stephen; Kelley, Mark C.; Khushalani, Nikhil I.; Kudchadkar, Ragini R.; Lange, Julie R.; Lind, Anne; Martini, Mary C.; Olszanski, Anthony J.; Pruitt, Scott K.; Ross, Merrick I.; Swetter, Susan M.; Tanabe, Kenneth K.; Thompson, John A.; Trisal, Vijay; Urist, Marshall M.; McMillian, Nicole; Ho, Maria.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 11, No. 4, 01.01.2013, p. 395-407.

Research output: Contribution to journalArticle

Coit, DG, Andtbacka, R, Anker, CJ, Bichakjian, CK, Carson, WE, Daud, A, DiMaio, DJ, Fleming, MD, Guild, V, Halpern, AC, Hodi, FS, Kelley, MC, Khushalani, NI, Kudchadkar, RR, Lange, JR, Lind, A, Martini, MC, Olszanski, AJ, Pruitt, SK, Ross, MI, Swetter, SM, Tanabe, KK, Thompson, JA, Trisal, V, Urist, MM, McMillian, N & Ho, M 2013, 'Melanoma, version 2.2013: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 11, no. 4, pp. 395-407. https://doi.org/10.6004/jnccn.2013.0055
Coit, Daniel G. ; Andtbacka, Robert ; Anker, Christopher J. ; Bichakjian, Christopher K. ; Carson, William E. ; Daud, Adil ; DiMaio, Dominick J ; Fleming, Martin D. ; Guild, Valerie ; Halpern, Allan C. ; Hodi, F. Stephen ; Kelley, Mark C. ; Khushalani, Nikhil I. ; Kudchadkar, Ragini R. ; Lange, Julie R. ; Lind, Anne ; Martini, Mary C. ; Olszanski, Anthony J. ; Pruitt, Scott K. ; Ross, Merrick I. ; Swetter, Susan M. ; Tanabe, Kenneth K. ; Thompson, John A. ; Trisal, Vijay ; Urist, Marshall M. ; McMillian, Nicole ; Ho, Maria. / Melanoma, version 2.2013 : Featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2013 ; Vol. 11, No. 4. pp. 395-407.
@article{061a45e4dd984173a1ca6ea01f5b7e5a,
title = "Melanoma, version 2.2013: Featured updates to the NCCN guidelines",
abstract = "The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases, and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel reached clinical consensus on clarifying the role of imaging in the workup of patients with melanoma.",
author = "Coit, {Daniel G.} and Robert Andtbacka and Anker, {Christopher J.} and Bichakjian, {Christopher K.} and Carson, {William E.} and Adil Daud and DiMaio, {Dominick J} and Fleming, {Martin D.} and Valerie Guild and Halpern, {Allan C.} and Hodi, {F. Stephen} and Kelley, {Mark C.} and Khushalani, {Nikhil I.} and Kudchadkar, {Ragini R.} and Lange, {Julie R.} and Anne Lind and Martini, {Mary C.} and Olszanski, {Anthony J.} and Pruitt, {Scott K.} and Ross, {Merrick I.} and Swetter, {Susan M.} and Tanabe, {Kenneth K.} and Thompson, {John A.} and Vijay Trisal and Urist, {Marshall M.} and Nicole McMillian and Maria Ho",
year = "2013",
month = "1",
day = "1",
doi = "10.6004/jnccn.2013.0055",
language = "English (US)",
volume = "11",
pages = "395--407",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - Melanoma, version 2.2013

T2 - Featured updates to the NCCN guidelines

AU - Coit, Daniel G.

AU - Andtbacka, Robert

AU - Anker, Christopher J.

AU - Bichakjian, Christopher K.

AU - Carson, William E.

AU - Daud, Adil

AU - DiMaio, Dominick J

AU - Fleming, Martin D.

AU - Guild, Valerie

AU - Halpern, Allan C.

AU - Hodi, F. Stephen

AU - Kelley, Mark C.

AU - Khushalani, Nikhil I.

AU - Kudchadkar, Ragini R.

AU - Lange, Julie R.

AU - Lind, Anne

AU - Martini, Mary C.

AU - Olszanski, Anthony J.

AU - Pruitt, Scott K.

AU - Ross, Merrick I.

AU - Swetter, Susan M.

AU - Tanabe, Kenneth K.

AU - Thompson, John A.

AU - Trisal, Vijay

AU - Urist, Marshall M.

AU - McMillian, Nicole

AU - Ho, Maria

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases, and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel reached clinical consensus on clarifying the role of imaging in the workup of patients with melanoma.

AB - The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates. Foremost of these is the exciting addition of the novel agents ipilimumab and vemurafenib for treatment of advanced melanoma. The NCCN panel also included imatinib as a treatment for KIT-mutated tumors and pegylated interferon alfa-2b as an option for adjuvant therapy. Also important are revisions to the initial stratification of early-stage lesions based on the risk of sentinel lymph node metastases, and revised recommendations on the use of sentinel lymph node biopsy for low-risk groups. Finally, the NCCN panel reached clinical consensus on clarifying the role of imaging in the workup of patients with melanoma.

UR - http://www.scopus.com/inward/record.url?scp=84877996512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877996512&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2013.0055

DO - 10.6004/jnccn.2013.0055

M3 - Article

C2 - 23584343

AN - SCOPUS:84877996512

VL - 11

SP - 395

EP - 407

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 4

ER -